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Abstract
Drug-induced liver injury (DILI) is largely a diagnosis of exclusion and is therefore challenging.
The US Drug-Induced Liver Injury Network (DILIN) prospective study used two methods to
assess DILI causality: a structured expert opinion process and the Roussel-Uclaf Causality
Assessment Method (RUCAM). Causality assessment focused on detailed clinical and laboratory
data from patients with suspected DILI. The adjudication process used standardized numerical and
descriptive definitions and scored cases as definite, highly likely, probable, possible, or unlikely.
Results of the structured expert opinion procedure were compared with those derived by the
RUCAM approach. Among 250 patients with suspected DILI, the expert opinion adjudication
process scored 78 patients (31%) as definite, 102 (41%) as highly likely, 37 (15%) as probable, 25
(10%) as possible, and 8 (3%) as unlikely. Among 187 enrollees who had received a single
implicated drug, initial complete agreement was reached for 50 (27%) with the expert opinion
process and for 34 (19%) with a five-category RUCAM scale (P = 0.08), and the two methods
demonstrated a modest correlation with each other (Spearman's r = 0.42, P = 0.0001). Importantly,
the RUCAM approach substantially shifted the causality likelihood toward lower probabilities in
comparison with the DILIN expert opinion process.
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Conclusion—The structured DILIN expert opinion process produced higher agreement rates and
likelihood scores than RUCAM in assessing causality, but there was still considerable
interobserver variability in both. Accordingly, a more objective, reliable, and reproducible means
of assessing DILI causality is still needed.
A diagnosis of hepatotoxicity must be considered when liver injury is identified in a person
taking a prescription drug, herbal, or over-the-counter product, even if there is already
preexisting liver disease.1-5 Because there is currently no specific marker of drug-induced
liver injury (DILI), the diagnosis rests on excluding other conditions that can mimic such
injury. The diagnosis is especially difficult when affected persons are taking multiple
products, any one of which might be responsible, and because of possible synergism
between drugs.1,6-8
In the traditional diagnostic approach to suspected DILI, which involves clinical,
biochemical, and histological evaluation, attempts are made to establish the latency between
the start of the drug and the onset of injury, its clinical signature, the exclusion of alternate
etiologies, evidence of improvement of the liver injury upon drug withdrawal (dechallenge),
and the effect of deliberate or inadvertent rechallenge. When performed by an experienced
clinician, the assessment is considered by expert opinion. However, even for experts, the
diagnosis of DILI can be problematic because of the inherently subjective nature of this
approach. Efforts have therefore turned toward developing more objective diagnostic
strategies through the creation of specific instruments such as the Roussel-Uclaf Causality
Assessment Method (RUCAM), the Maria and Victorino method, and the Naranjo scale, the
last designed to assess all forms of adverse drug reactions.9-13 In a head-to-head comparison
of these instruments, RUCAM has been found to perform best for diagnosing hepatotoxicity,
but it is cumbersome and therefore is rarely used in clinical practice.
The Drug-Induced Liver Injury Network (DILIN) is a multicenter study whose primary aims
are to identify and collect information on bona fide cases of drug-induced liver disease and
to obtain serum, DNA, and liver tissue to allow for mechanistic investigation. When the
study was being planned, the decision was made to assess causality with both expert opinion
and RUCAM. A highly structured expert opinion method was developed that was
specifically designed to include standardized terminology and specific methodology, and it
is hereafter called structured expert opinion. It was hypothesized that this approach may
have certain advantages in comparison with RUCAM. This report describes how the expert
opinion approach was developed and refined and compares its effectiveness to that of
RUCAM.14
Patients and Methods
Established in 2003, DILIN originally comprised five clinical sites (and their affiliates), a
data coordinating center (DCC), a serum, DNA, and tissue repository, and a central
histopathology core.15 The study has since expanded to include eight clinical sites. Network
investigators were charged with identifying and enrolling persons who developed DILI,
carefully phenotyping the clinical condition, and collecting appropriate biological samples.
Details concerning the planning, initial study design, study outcomes, eligibility criteria, and
conduct of the study have been reported,14 and the clinical features of the first 300 patients
enrolled have been summarized.16 The study protocols were approved by the institutional
review boards at all participating institutions and were registered at ClinicalTrials.gov.
Eligibility Requirements for the Prospective Study
In brief, enrollees in the prospective study were persons receiving single or multiple drugs,
herbals, or other over-the-counter products identified to have biochemically defined liver
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dysfunction, provided that they could be evaluated within 6 months of onset of the liver
disease.14 Biochemical criteria for enrollment included (1) two consecutive serum alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) values > 5 times the upper
limit of normal (ULN) or > 5 times the baseline abnormal value, (2) two consecutive serum
alkaline phosphatase (AP) values greater than twice the ULN or twice the baseline abnormal
value, or (3) an otherwise unexplained total serum bilirubin value > 2.5 mg/dL or an
international normalized ratio (INR) > 1.5 on two consecutive occasions. Symptoms or signs
of liver injury were not required. Exclusion criteria were liver injury due to acetaminophen,
preexisting autoimmune hepatitis or sclerosing cholangitis, and previous receipt of a bone
marrow or liver transplant. Persons were not excluded for preexisting chronic hepatitis B or
C or human immunodeficiency virus infection, provided that baseline laboratory test results
were available.
Structured DILIN Expert Opinion Process
Sequential steps in causality assessment are outlined in Fig. 1. Complete clinical data,
including serial laboratory test results together with the local ULN values, were extracted
from the clinical records and entered into a 65-page case report form (CRF). To exclude
conditions that can mimic drug-induced liver disease, the patients and their medical records
were screened for previous liver disease, alcohol use, serological and virological evidence of
hepatitis A, B, or C infection, autoantibodies, ceruloplasmin, alpha-1-antitrypsin, ferritin,
and iron; additionally, results of imaging studies were reviewed. Patients who had not been
fully evaluated when they were first identified underwent testing for any missing laboratory
data at enrollment. Liver biopsy was not required for adjudication purposes, but if it was
performed as part of routine clinical care, the results were collected and made available to
reviewers. To facilitate adjudication, the extensive database was summarized in an
abbreviated CRF that included such key elements as the date of onset of liver injury,
complete information about all medications taken within 6 months of onset of the event, the
presence of symptoms and signs of liver disease, pertinent past medical history, complete
laboratory tests, imaging and liver biopsy results, and serial results for ALT, AST, AP,
serum bilirubin, and the prothrombin time or INR.
In addition to the short CRF summary, a succinct case summary called the clinical narrative
was completed by the study investigator who enrolled the subject. The narrative provided
detailed information on the history and chronology of the illness with dates of drug initiation
and liver disease onset, pertinent features of the liver disease, and the time to improvement
or recovery. The narrative also included information on past use of the implicated agent and
significant concomitant drugs, the past medical history, the extent of alcohol use, whether
there had been an episode of hypotension, and information on the course of the illness,
including hospitalization, a history of hepatic decompensation or organ failure, and death or
liver transplantation. Finally, the investigator provided a rationale for ascribing the event to
a specific medication or medications without offering a personal view on the estimated
strength of the association.
Origin and Status of the Reviewers
The CRF summary and clinical narrative were first assessed by the DCC for consistency and
omissions and, after approval, were forwarded to three reviewers, including the submitting
investigator and two members of the DILIN causality committee from other sites. The three
reviewers each worked independently, without knowledge of who the other two were or
what scores they awarded. The two nonsubmitting reviewers were selected in rotation from
the full causality committee, which consisted of principal investigators and coprincipal
investigators from the five clinical sites and the DCC and project officers and scientific
advisors from the National Institute of Diabetes and Digestive and Kidney Diseases (see
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Appendix 1 in the supporting information). All the reviewers were hepatologists with
experience in evaluating DILI. All contributed to the design of the study and, from the
outset, participated in an in-depth discussion of the issues related to hepatotoxicity and in
fashioning the DILIN causality process through frequent conference calls, e-mail
communications, and face-to-face meetings. This allowed for the thorough evaluation of the
scoring systems and ended in the development of standard operating procedures for both the
DILIN system and RUCAM. The RUCAM standard operating procedure was generated
after one of its originators was contacted for clarification purposes and with a broad
examination of relevant literature. Thereafter, experience was gained by frequent discussion
of representative examples of DILI and by re-review of specific cases.
To avoid a conflict of interest, reviewers who had a declared relationship with the
manufacturer of any implicated drug were excluded. Detailed conflict-of-interest forms were
completed annually by all DILIN participants.
DILIN Adjudication Process
After independently evaluating the cases, each reviewer, using a five-point or category scale,
provided an assessment of the likelihood that the medication caused the liver injury. They
also completed a RUCAM form (see Appendix 2 in the supporting information) and used
the instructions provided with the form. Information necessary to complete the RUCAM
assessment was included in the short CRF and the clinical narrative.
The five-point (category) DILIN likelihood causality scale used both a percentage figure and
descriptive legal terminology to grade cases as definite, highly likely, probable, possible, or
unlikely (Table 1). Causality was considered to be definite if attribution of the drug to the
liver injury was believed to exceed 95% likelihood with an association beyond a reasonable
doubt. Cases were awarded this grade if the medication was well recognized to cause liver
injury, it had a characteristic or typical signature, and there was no evidence of a competing
diagnosis. The designation highly likely was applied when there was an estimated 75% to
95% likelihood of an association and by the legal phrase indicating clear and convincing
evidence for the association. These cases were regarded as convincingly due to the
medication, with minor reservations because of a somewhat atypical course or presentation
or the remote possibility of another diagnosis. Cases were called probable when the
likelihood of an association was considered to be between 50% and 75%, with legal
terminology indicating that the association was supported by the predominance of the
evidence. Although appearing to show an association, such cases would not be graded
higher because of an atypical course, the absence of essential clinical information, or the
presence of another possible explanation or diagnosis. Cases were considered to be possible
if they were believed to have a 25% to 50% likelihood of an association because, although it
was still possibly related, the involvement by the drug was equivocal and was not supported
by the preponderance of the evidence. Cases were ranked as unlikely if they were regarded
to have less than a 25% likelihood of resulting from the medication, and another etiology
was considered to be responsible. These definitions attached semiquantitative values to these
inherently subjective terms and brought increased uniformity to the adjudication process.
For a more complete summary of the definitions of each category, please see Supporting
Table 1.
If more than one drug, herbal, or nutritional supplement was considered potentially
responsible, a separate assessment by expert opinion and RUCAM was completed for each
drug. The case was assessed first for the overall likelihood that a drug caused liver disease
with the five-category DILIN scale, and then each drug (up to three were allowed) was
assessed separately. Combination drugs, such as amoxicillin/clavulanate, trimethoprim/
sulfamethoxazole, and the majority of herbal preparations, were assessed as if they were a
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single agent without an attempt to appraise the role of each component separately.
Implicated drugs graded for likelihood by the three reviewers were assessed also for the
severity of the liver injury by a single reviewer, and the results were submitted to the DCC
for addition to the database.
A causality conference call was arranged monthly to review cases adjudicated for that month
by the three reviewers using the structured expert opinion method and RUCAM. If all three
had independently reached the same causality scores before the call, this was accepted as a
final result and not discussed further. If, however, there was discrepancy among the three
reviewers, the chair of the causality committee attempted to reconcile the differences among
them before the conference call through open and transparent dialogue. If accord was still
not reached at the time of the conference call, the three reviewers were given one last
opportunity on the call to reach agreement. Failing to find consensus, the full causality
committee then voted on the case, and the majority result was accepted as the final score.
Liver biopsy was performed inconsistently and often at different stages in the course of the
liver injury. For these reasons, liver biopsy was not used as a formal feature of the
adjudication process. However, local biopsy readings were available to reviewers.
Statistics
Standard descriptive statistics were used to summarize the features of enrolled patients,
which included demographic characteristics, signs and symptoms, laboratory data, and type
of injury. To assess discrepancies, pairwise differences among the three primary reviewers
were first compiled, and the maximum of the absolute values of these differences [the
maximum absolute difference (MAD) among them] was recorded. Spearman's correlation
was used to assess the association between the RUCAM and DILIN structured expert
opinion scores. Between-group comparisons of the DILIN causality score were made with
Fisher's exact test. McNemar's test17 was used to compare the rate of complete agreement
among the three reviewers in the two causality approaches.
Results
Characteristics of the Study Cohort
The analysis focused on the first 250 adjudicated cases, 187 (75%) of whom had received a
single drug or herbal product. Their demographic, clinical, and biochemical features (Table
2) closely resembled those of the 300 patients in the prospective study previously
described.16 The average age of the patients was 49 years, and 58% were women.
Approximately two-thirds were jaundiced (bilirubin > 2.5 mg/dL), 58% were hospitalized,
and 5% died within 6 months of onset of liver injury or required liver transplantation.
Although almost 20% of the subjects reported during the initial interview that they had had
prior liver disease, objective evidence for this was present in only 6%, the most common
cause being underlying hepatitis C virus infection.
The liver injury was attributed to a wide variety of drugs and herbal products, which
included antimicrobials (46%), central nervous system agents (15%), immunomodulatory
agents (7%), herbals (5%), anti-neoplastic agents (4%), lipid-lowering agents (4%),
analgesics (3%), and others (16%). The most frequent presenting pattern of injury was that
of hepatocellular liver disease (i.e., R value ≥ 5).18
Causality Assessment Using the DILIN Structured Expert Opinion Adjudication Process
Causality assessment by the structured expert opinion method was conducted in two phases,
the first consisting of the frequency with which the three independent reviewers reached
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initial common agreement and the second consisting of the frequency with which they were
willing to alter their initial causality grade after group discussion. The frequency of initial
agreement among the three reviewers was relatively high, as indicated by the MAD in
causality assessment scores for the 250 assessed cases (Table 3). All three agreed in the
assessment in 27% of the cases (MAD of 0), and there was agreement by two of the three in
another 43% of patients, the third reviewer differing by only one category or point (MAD of
1).
Results of the final assessment using the DILIN structured expert opinion approach and its
comparison with the initial assessment are shown in Table 4. The two most frequent scores
assigned initially by the three reviewers were definite and highly likely, and these
evaluations changed little at the final assessment. Thus, the final conclusion was that 31% of
cases were considered definite, 41% were highly likely, 15% were probable, 10% were
possible, and 3% were unlikely. In general, when the full causality committee voted on
adjudication, they tended to adopt the majority opinion reached among the three reviewers,
unless one reviewer established compelling evidence to the contrary.
Comparison of the DILIN Expert Opinion Adjudication Process and the RUCAM Method
All cases were assessed by each reviewer separately with both the DILIN structured expert
opinion approach and RUCAM; the results of the two are compared for the 187 patients who
had received a single drug (Table 5). Because each case had been evaluated by three
reviewers, the total number of reviews should have totaled 561; all 561 reviews were
completed with the expert opinion approach, but 4 were missing for RUCAM, so completion
of 557 scores (99.3%) was permitted. RUCAM assigns scores that range from +15 to −3,
with highly probable requiring a score of >8, probable requiring a score of 6 to 8, possible
requiring a score of 4 to 6, and unlikely requiring a score of 1 to 3; DILI is excluded for a
score of <1.
Reviewers, using structured expert opinion, scored 409 cases (196 + 213) as definite or
highly likely (total of 72%), but only 132 (24%) were assigned the equivalent RUCAM
score of highly probable (Table 5). Furthermore, although reviewers scored 22 cases (4%) as
unlikely with the DILIN structured expert opinion process, 38 of the cases (8%) were
assessed correspondingly by RUCAM as either unlikely (22) or excluded (16). Finally,
although the structured expert opinion method scored 23.1% of the cases as either probable
or possible, RUCAM attributed 69.5% of the cases to the equivalent probable or possible
categories. These comparative results are displayed in a box and whisker plot (Fig. 2). There
was considerable variability in the comparison of the RUCAM score to each level of the
DILIN structured expert opinion scores, with RUCAM displaying lower levels of causality
(Spearman's correlation, r = 0.42 in absolute value; P = 0.0001).
A comparison of the agreement among the reviewers in causality assessment between the
structured expert opinion and RUCAM methods, restricted to the 187 patients who had
received only a single drug, is shown in Table 6. Complete agreement (MAD = 0) was
reached in 27% with expert opinion versus 19% with RUCAM (P = 0.08). The average
MAD was 1.12 with the DILIN strategy and 1.18 with the RUCAM strategy.
In order to adequately assess the relationship between the conclusions of the DILIN process
and RUCAM, it should be possible to directly compare the results of the two different
assessment methods. Such a comparison is, however, compromised by the fact that, even
though both systems use five levels of likelihood, the terminological differences hinder a
direct comparison. In an effort to circumvent this problem, two different types of
comparisons were undertaken.
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The first consisted of directly comparing the results of the two approaches in a 5 × 5 table
with the established terms for each of them, even though an individual term, such as
possible, might not have the identical weight. Nevertheless, the comparison is based on the
relative ranking on the two ordinal scales. As shown in cross-tabulation (diagonal box) in
Table 7, there was agreement in the relative ranking in 230 of the 557 reviews (41.3%).
Moreover, scores fell within one category of each other in 479 reviews (86.0%). The
majority of cases scored at DILIN's highest causality category (definite) were scored at
lower levels by RUCAM. Similarly, disagreements at DILIN's second causality level (very
likely) were scored more often at lower causality levels by RUCAM. In contrast,
disagreements at DILIN's third and fourth causality levels (probable and possible) were
scored more often at higher causality levels by RUCAM. Thus, RUCAM graded more cases
in the middle ranges, whereas the DILIN process scored a greater number of cases in higher
and lower likelihood categories.
A second analysis took into account the fact that a score of probable or higher in both
systems would probably signify a valid case of DILI. Thus, the comparison was collapsed
into a 2 × 2 table, and the outcomes for both were separated into “yes = DILI” and “no = not
DILI” (Table 8). Even at this most basic level, there was agreement in only 384 of the
reviews (68.9%), as displayed in the cross-tabulation. In this analysis, the DILIN expert
opinion process was more likely than RUCAM to ascribe the case to DILI [DILIN, 495/557
(88.9%) versus RUCAM, 352/557 (63.2%)].
Discussion
Because there is no specific objective marker of drug-induced liver disease, an accurate
diagnosis of hepatotoxicity has constantly been challenging. DILI must always be
considered, however, when there is a temporal association between observed liver injury and
the receipt of a drug. The warning signal has been either an acute onset of clinical symptoms
(e.g., rash, fever, abdominal pain, or jaundice) or, more commonly, biochemical
dysfunction, which includes raised levels of ALT, AST, AP, gamma-glutamyl
transpeptidase, and/or serum bilirubin.1,19,20 Although these abnormalities strongly suggest
liver disease, they are in fact nonspecific indicators and, moreover, do not provide an
etiological diagnosis.
The use of expert opinion to identify DILI has long been regarded as the gold standard for
diagnosing hepatotoxicity, especially when reports come from well-recognized authorities
rather than from an inexperienced occasional observer.2-5,21,22 However, because this
approach is subjective and lacks defined criteria, a group of international experts convened a
meeting under the auspices of the Council for International Organizations of Medical
Scientists with the goal of introducing structure and uniformity to the causality process
through the development of highly defined diagnostic criteria for drug-induced liver disease.
The meeting was supported by Roussel-Uclaf Pharmaceuticals, and hence the instrument is
called RUCAM. The strategy awards points for seven different domains.10 Other attempts
have been made to develop causality instruments with the hope of simplifying the
adjudication process,11,23 but the value of some has been questioned24; this has left
RUCAM as the preferred causality instrument. Although used by some experts in the field
and often referred to in discussing DILI causality, RUCAM has not been adopted in general
clinical practice or, in fact, by most practicing hepatologists and gastroenterologists. The
chief reason is that it is a time-consuming process with insufficient and sometimes confusing
information on how to score some of the elements of its domains. Nevertheless, during the
planning for DILIN, the decision was made to use and compare two approaches for
establishing causality: a refined and highly structured expert opinion method and the
RUCAM instrument.
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A direct comparison of the DILIN structured expert opinion and RUCAM revealed that the
DILIN process was more likely than RUCAM to generate a score supportive of drug-
induced liver disease. Using the DILIN system, reviewers scored 73% of cases (405/557) as
definite or highly likely, whereas only 24% of the cases (132/557) were scored as highly
probable in the corresponding RUCAM category (Table 6). Indeed, the DILIN process
grouped subjects more toward the definite/highly likely category, whereas the same cases
evaluated by RUCAM were scored in the middle ranges (probable/possible), and this
suggested that RUCAM skewed the distribution toward a lesser overall likelihood. The
RUCAM approach was thus more conservative in assigning a high level of causality than
the DILIN strategy. A drawback to this comparison, however, is that the two grading
categories are not strictly parallel, and collapsing of categories was required to bring them to
a reasonable accord. Furthermore, such grouping of categories was not part of the actual
design of either causality method.
Also of note is the fact that the DILIN approach afforded substantially greater agreement in
the initial blinded evaluation than the RUCAM approach. With the DILIN system, all three
reviewers agreed completely in 50 of the cases (27%), and they disagreed by only one point
in an additional 83 (44%); they thus achieved generally similar conclusions in 70% of the
adjudicated cases. In contrast, when RUCAM, restricted to persons who had received only a
single agent, was used, complete agreement was even lower at 19% of subjects (34/187).
This is somewhat surprising because RUCAM was designed to be an objective causality
score. The variability is likely due to the ambiguities of some of the RUCAM score
parameters. Nevertheless, even though there was greater reviewer agreement with the DILIN
structured expert opinion method than with the RUCAM approach, there was still
disagreement in almost one-third of cases with the DILIN adjudication method. This is not
unexpected, however, because the structured expert opinion process persists in being a
subjective form of assessment until a definitive diagnostic marker is established, and thus
assessments will continue to vary according to individual reviewer perspectives. Indeed,
difficulties in reaching consensus among multiple reviewers working independently have
been described previously,25 although disagreements appear less likely when reviewers are
experts trained in the use of a standardized causality assessment method.26,27
The RUCAM scoring system appears to be problematic even for experienced persons, let
alone for nonexpert health professionals in clinical practice. Indeed, in a previous report
from the DILIN study group, RUCAM was found to have poor reproducibility, even when
repeated by the same reviewers.28 However, as already noted, the refined expert opinion
process developed for this study also has its limitations. One of these is that there was
unquestionably selection bias in recruiting subjects into this study because the site
investigators, all experts, tended to choose cases with a high probability of a diagnosis of
DILI, especially those with severe injury. Nevertheless, identical cases were reviewed by the
two modalities, so any bias would apply to both systems. Another limitation is that the
DILIN approach used three and sometimes more expert reviewers, a luxury not available in
routine practice, and this limits its general clinical applicability. Most important is that,
without a specific diagnostic biomarker, adjudication by expert opinion remains subjective
in the hands of even highly experienced clinician investigators.
In conclusion, the goal of this network study was to develop a carefully standardized
approach for assessing DILI that would yield high-quality and consistent results because it
involved experienced hepatologists. Additionally, it was believed that the use of RUCAM
would complement the expert opinion approach. Instead, the correlation between the two
adjudication methods was weak. Indeed, neither approach, as currently designed, can be
considered fully effective for assessing causality of DILI outside a research setting. There is
clearly a need for a more objective, quantitative, and effective method of adjudication for
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drug-induced liver disease. Undoubtedly, such an instrument would contain many of the
fields currently included in the RUCAM instrument, but it would require modifications and
improved, more user-friendly definitions and may ultimately include genomic and/or
proteomic assessment. The components of such an instrument would require careful and
precise definitions without ambiguity. Moreover, this new instrument would ideally be
developed in a web-based, computerized form that could be programmed to rapidly produce
a meaningful score. The DILIN study continues to work with this goal in mind.
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Fig. 1.
Overview of the DILIN causality adjudication process. A flow diagram of the different steps
in the entire causality process is shown.
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Fig. 2.
Correlation of the RUCAM and DILIN causality scores. A box and whisker plot of the
RUCAM score at each level of the DILIN expert opinion score is shown. There is a general
relationship between the two scales (r = 0.42 in absolute value), although there is
considerable variability in the RUCAM score at each DILIN score. [Color figure can be
viewed in the online issue, which is available at www.interscience.wiley.com.]
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Table 1
Clinical Assessment of Causality Scale: Definitions
Label (Score) Likelihood Description
Definite (1) >95% The evidence for the drug causing the injury is beyond a reasonable doubt.
Highly likely (2) 75%-95% The evidence for the drug causing the injury is clear and convincing but not definite.
Probable (3) 50%-74% The preponderance of the evidence supports the link between the drug and the liver injury
Possible (4) 25%-49% The evidence for the drug causing the injury is equivocal but present.
Unlikely (5) <25% There is evidence that an etiological factor other than a drug caused the injury.
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Table 2
Demographic and Clinical Characteristics
Characteristic Mean ± Standard Deviation/%*
Demographics
 Age at DILI onset (n = 249) 48.5 ± 18.6
 Age ≥ 55 years (n = 249) 37.3%
 Gender: female 57.6%
 Ethnicity: not Hispanic or Latino 92.8%
 Race (n = 249)
  White 78.3%
  Black or African American 13.7%
Prior history
 Prior history of a liver problem 19.2%
 Prior allergy to a medication (n = 247) 53.4%
Body mass index at DILI onset (n = 231) 26.5 ± 6.5 kg/m2
At least one alcoholic drink prior to drug use (n = 248) 52.8%
Days from drug exposure to DILI recognition [median (25th percentile, 75th percentile)] 42 (20, 106.5)
Hospitalized (n = 249) 58.2%
Time from onset of illness to presentation
 <1 week 8.4%
 1 week 3.2%
 2–4 weeks 27.2%
 >4 weeks 61.2%
Prescribed prednisone 18.8%
Death or orthotopic liver transplantation 5%
Selected symptoms and signs
 Jaundice† 66.0%
 Nausea 63.2%
 Anorexia 56.0%
 Itching 52.8%
 Abdominal pain 49.6%
 Vomiting 40.4%
 Fever 32.8%
 Rash 29.6%
 Ascites 10.0%
 Hepatomegaly 7.2%
 Splenomegaly 2.4%
 Lymphadenopathy 1.6%
Peak liver tests (n = 249)
 Peak AST (×ULN) 21.1 ± 34.3
 Peak ALT (×ULN) 18.4 ± 19.5
 Peak AP (×ULN) 2.9 ± 3.0
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Characteristic Mean ± Standard Deviation/%*
 Peak serum total bilirubin (×ULN) 9.0 ± 8.9
 INR (n = 213) 1.6 ± 1.6
Eosinophil count (n = 57) 200.6 ± 196.8
Pattern of liver injury (n = 249)‡
 Hepatocellular (R ≥ 5) 55.4%
 Mixed (2 < R < 5) 22.1%
 Cholestatic (R ≤ 2) 22.5%
*
Based on 250 cases unless otherwise indicated.
†
Jaundice was based on clinical criteria (yellow sclera, skin, or both).
‡
R is defined as (ALT/ULN)/(AP/ULN) at the time of onset.
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Table 3
MAD at the Initial Evaluation of All 250 Cases Using the DILIN Structured Expert
Opinion Assessment Method
MAD Frequency %
0 67 27
1 108 43
2 51 20
3 24 10
The average was 1.13.
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Table 4
Distribution of Initial and Final Scores Using the DILIN Structured Expert Opinion
Strategy
DILIN Causality Score
Initial Reviewer Scores
(n = 750)
Final Committee Scores
(n = 250)
Frequency % Frequency %
Definite 241 32.1 78 31.2
Highly likely 305 40.7 102 40.8
Probable 119 15.9 37 14.8
Possible 58 7.7 25 10.0
Unlikely 27 3.6 8 3.2
Initial reviewer scores are based on three reviewers per case; committee scores are based on the final score per case.
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Table 5
Distribution of Causality Scores at the Initial Evaluation
A. DILIN Structured Expert Opinion Score (n = 187)†
Likelihood Frequency %
Definite 196 34.9
Highly likely 213 37.9
Probable 86 15.3
Possible 44 7.8
Unlikely 22 3.9
Total 561 100.0
B. RUCAM (n = 187)†
Likelihood Frequency %
Highly probable 132 23.7
Probable 220 39.5
Possible 167 30.0
Unlikely 22 4.0
Excluded 16 2.9
Total 557 100.0
†
Each case was evaluated by three reviewers, and this yielded 561 reviews.
†
The RUCAM categories were as follows: highly probable, >8; probable, 6 to 8; possible, 3 to 5; unlikely, 1 to 2; and excluded, <1. RUCAM
scores were missing for 4 reviews, so there were 557 reviews instead of 561.
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Table 6
MAD Among the Reviewers in the Two Causality Scales During the Initial Review
Process
MAD
DILIN Structured Expert Opinion Score RUCAM
Frequency % Frequency %
0 50 26.7 34 18.6
1 83 44.4 92 50.3
2 25 18.7 48 26.2
3 19 10.2 8 4.4
4 0 0 1 0.6
Average 1.12 1.18
This table is restricted to cases in which a single agent was implicated and reviews were available from all three reviewers. There were 187 cases
for the causality score and 183 cases for RUCAM.
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Table 8
Condensed Cross-Tabulation of Initial DILIN and RUCAM Scoresa
DILIN Expert Opinion Process
RUCAM
TotalYes No
Yes 335 156 491
No 17 49 66
Total 352 205 557
a
This table is restricted to cases in which a single agent was implicated (n = 187 cases). RUCAM scores were missing for 4 reviews, and this
resulted in 557 reviews.
b
For each DILIN and RUCAM, yes = probable or higher; no = possible or lower.
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